Skip to search formSkip to main contentSkip to account menu

Haloperidol

Known as: Haloperidol [Chemical/Ingredient], 1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine, 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone 
A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1984
Highly Cited
1984
The relationship between clinical response of schizophrenic patients to haloperidol and (1) blood levels of the medication… 
1983
1983
Prolactin secretion was stimulated in 5 cyclic gilts during the luteal phase (Day 10-13) with 5 mg haloperidol given i.v… 
Highly Cited
1981
Highly Cited
1981
Adrenergic and dopaminergic agonists administered in vivo stimulate GH secretion and inhibit PRL release. To investigate the… 
1980
1980
Short-term haloperidol treatment decreases the stimulant effects of drugs with dopaminelike actions, while withdrawal from long… 
1978
1978
Prompted by an interest in the similarity of brain and tuberoinfundibular systems, the authors studied butaclamol-specific… 
1978
1978
To investigate further possible direct effects of dopamine agonists and antagonists upon the lactotropic cell in vivo, the PRL… 
Highly Cited
1976
Highly Cited
1976
Fentanyl in low doses (0.02-0.05 mg/kg) had no significant effect on the dopamine turnover 20 min after intraperitoneal (i.p… 
Highly Cited
1975
Highly Cited
1975
The purpose of this investigation was to develop a system for studying the effects of dopamine on isolated blood vessels. Canine… 
Highly Cited
1973
Highly Cited
1973
Data are presented from a multidimensional, longitudinal study in 10 acute schizophrenics which indicate that the addition of… 
1968
1968
The authors report a clinical study of the efficacy of a butyrophenone derivative (haloperidol) in a sample of mentally retarded…